Blair N P, Baker D S, Rhode J P, Solomon M
University of Illinois, Chicago Eye Center 60612.
Arch Ophthalmol. 1989 Mar;107(3):417-23. doi: 10.1001/archopht.1989.01070010427039.
No satisfactory treatment is available to supply the metabolic needs of the retina in vascular occlusion. Consequently, necrosis occurs. We devised vitreoperfusion, a technique of perfusing the vitreous cavity after vitrectomy-lensectomy with selected fluids containing glucose and oxygen. We tested whether vitreoperfusion could protect the retina from severe combined retinal and choroidal ischemia. An intraocular pressure of 170 mm Hg was induced in each eye of nine cats for up to four hours, and simultaneously one eye of each cat underwent vitreoperfusion. After one week, histopathologic examination revealed retinal atrophy and dissolution in untreated eyes but not in eyes treated with vitreoperfusion. To our knowledge, such severe ischemia has never been treated successfully before. Vitreoperfusion is a potential treatment modality in various forms of ocular ischemia. Additional studies are warranted to refine the technique and determine any clinical applicability.
对于血管阻塞性疾病,目前尚无令人满意的治疗方法来满足视网膜的代谢需求。因此,会发生坏死。我们设计了玻璃体灌注术,这是一种在玻璃体切割术-晶状体切除术后,用含有葡萄糖和氧气的特定液体灌注玻璃体腔的技术。我们测试了玻璃体灌注术是否能保护视网膜免受严重的视网膜和脉络膜联合缺血的影响。对9只猫的每只眼睛施加170毫米汞柱的眼压长达4小时,同时每只猫的一只眼睛接受玻璃体灌注。一周后,组织病理学检查显示,未治疗的眼睛出现视网膜萎缩和溶解,而接受玻璃体灌注治疗的眼睛则未出现这种情况。据我们所知,如此严重的缺血此前从未得到成功治疗。玻璃体灌注术是治疗各种眼部缺血性疾病的一种潜在治疗方式。有必要进行更多研究以完善该技术并确定其临床适用性。